Ferdosi, Shayesteh R. http://orcid.org/0000-0002-2550-8789
Ewaisha, Radwa http://orcid.org/0000-0002-7473-9831
Moghadam, Farzaneh http://orcid.org/0000-0003-3300-4027
Krishna, Sri http://orcid.org/0000-0003-4994-3758
Park, Jin G. http://orcid.org/0000-0001-6481-9590
Ebrahimkhani, Mo R. http://orcid.org/0000-0001-5753-6779
Kiani, Samira http://orcid.org/0000-0003-2695-1501
Anderson, Karen S.
Article History
Received: 9 June 2018
Accepted: 19 March 2019
First Online: 23 April 2019
Competing interests
: The Arizona Board of Regents on behalf of Arizona State University has submitted a patent application (application number: PCT/US18/29937, filed 27 April 2018), with authors S.R.F., R.E., F.M., S.K., M.R.E., S.K. and K.S.A. The patent application was published on 24 Jan 2019 and it is awaiting national stage entry. It includes a methods and compositions for reducing an undesirable T cell immune response in human patients before or during gene therapy using the CRISPR/Cas9-based genetic modulation. Also, it includes DNA sequences of cas9-α2, -β2, -α2β2, and sequences of guide RNAs and primers. The remaining authors declare no competing interests.